Ezetimibe/Simvastatin
Brand names: Ezetimibe-Simvastatin, Vytorin
At a glance
- Medicare prescriptions, 2024
- 83,767
- Medicare drug cost
- $7.0M
- Average cost per prescription
- $84.01
- Clinicians who prescribed it
- 4,767
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): • In adults with primary hyperlipidemia. • In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH).
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Internal Medicine 33.5%
- Family Medicine 30.3%
- Cardiology 11.5%
- Nurse Practitioners 8.4%
- General Practice 4.6%
- Physician Assistants 2.9%
- Interventional Cardiology 2.7%
- Endocrinology & Diabetes 2.1%
- Geriatric Medicine 1.1%
- Pulmonology 0.4%
- Gastroenterology 0.3%
- Hospitalist 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 3% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +46%
- Tennessee +16%
- Ohio +16%
- Michigan +12%
- Georgia +3%
- Illinois (smallest change) −18%
- New York (smallest change) −17%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Northstar Rx LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg / 10 mg simvastatin | white capsule, 8 mm | G321 |
| 10 mg / 20 mg simvastatin | white capsule, 11 mm | G322 |
| 10 mg / 40 mg simvastatin | white capsule, 14 mm | G323 |
| 10 mg / 80 mg simvastatin | white capsule, 17 mm | G324 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
6 recalls since 2020
- May 2025 · Glenmark Pharmaceuticals Inc., USA · Class III
Failed Impurities/Degradation Specifications: Out of Specification (OOS) for related substances test for Anhydro Simvastatin at the 06-month time point during long-term stability study. - Oct 2021 · Golden State Medical Supply Inc. · Class II
Failed Excipient Specification; product manufactured using an excipient found to be OOS for conductivity - Oct 2021 · Golden State Medical Supply Inc. · Class II
Failed Excipient Specifications and Presence of Foreign Tablets/Capsules; product manufactured using an excipient found to be OOS for conductivity and some Ezetimibe and Simvastatin Tablets, 10 mg/10 mg were found in the bottle - Oct 2021 · Dr. Reddy's Laboratories, Inc. · Class II
Failed Excipient Specifications and Presence of Foreign Tablets/Capsules; product manufactured using an excipient found to be OOS for conductivity and some Ezetimibe and Simvastatin Tablets, 10 mg/10 mg were found in the bottle - Oct 2021 · Dr. Reddy's Laboratories, Inc. · Class II
Failed Excipient Specifications; product manufactured using an excipient found to be OOS for conductivity - Mar 2021 · Cardinal Health Inc. · Class II
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.